T. Rowe Price Associates
KITE

T. Rowe Price Associates’s Kite Pharma, Inc. KITE Stock Holding History

T. Rowe Price Associates’s Portfolio KITE Stock Details KITE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-2,683,954
Closed -$483M – 2675
2017
Q3 		$483M Sell
2,683,954
-2,431,685
-48% -$339M 0.08% 260
2017
Q2 		$530M Buy
5,115,639
+1,907,805
+59% +$156M 0.1% 239
2017
Q1 		$252M Buy
3,207,834
+1,673,340
+109% +$103M 0.05% 377
2016
Q4 		$68.8M Buy
1,534,494
+1,012,926
+194% +$49.7M 0.01% 700
2016
Q3 		$29.1M Buy
521,568
+281,826
+118% +$15.7M 0.01% 995
2016
Q2 		$12M Buy
239,742
+224,752
+1,499% +$11M ﹤0.01% 1254
2016
Q1 		$688K Buy
14,990
+3,810
+34% +$185K ﹤0.01% 1845
2015
Q4 		$689K Buy
+11,180
New +$787K ﹤0.01% 1819
2015
Q3 		– Sell
-137,350
Closed -$8.37M – 2562
2015
Q2 		$8.37M Buy
+137,350
New +$7.84M ﹤0.01% 1389

T. Rowe Price Associates's KITE Position: Q4 2017 in Review

T. Rowe Price Associates sold out of Kite Pharma, Inc. (KITE) in Q4 2017, closing a stake of 2,683,954 shares — an estimated $483M sold.

T. Rowe Price Associates first reported a position in KITE in Q2 2015 and held it in 9 quarters. The position peaked at $530M in Q2 2017. 0 funds tracked by Wall St. Rank hold KITE as of Q4 2017.

  • T. Rowe Price Associates reported no remaining Kite Pharma, Inc. position as of Q4 2017 after selling out during the quarter.
  • T. Rowe Price Associates sold 2,683,954 Kite Pharma, Inc. shares in Q4 2017, an estimated $483M.
  • T. Rowe Price Associates first reported a position in Kite Pharma, Inc. in Q2 2015 and held it in 9 quarters.
  • T. Rowe Price Associates's Kite Pharma, Inc. position peaked at $530M in Q2 2017.
  • 0 funds tracked by Wall St. Rank held Kite Pharma, Inc. as of Q4 2017.

Based on T. Rowe Price Associates's 13F filing for Q4 2017, filed 14 Feb 2018.